BioCentury | Aug 6, 2020
Emerging Company Profile

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

Versant’s Ridgeline incubator in Basel has launched Matterhorn with an off-the-shelf MR1T cell therapy designed to address a broader range of cancers than CAR T and TCR therapies. The company raised a $30 million series...
BioCentury | Aug 1, 2020
Translation in Brief

TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

SARS-CoV-2 binding sites for cytotoxic T cells TScan Therapeutics Inc. reported in medRxiv that memory CD8 + T cell responses against SARS-CoV-2 are dominated by a few epitopes in SARS-CoV-2. An analysis of samples from...
BioCentury | Jul 28, 2020
Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

The earliest clinical efficacy data for TCR2’s mesothelin-targeted TRuC T cell therapy hint that the engineered TCR T cells may work in solid tumors, where CAR T cells have yet to shine. Shares of TCR...
BioCentury | Jul 21, 2020
Deals

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

For the second time in as many months, Gilead has made a large investment in a biotech in the cancer immunosuppression area, paying $300 million up front to acquire nearly half of privately-held Tizona with...
BioCentury | Jun 23, 2020
Tools & Techniques

AI tools against COVID-19: a view from where the rubber hits the road

Making machine learning an effective tool in the fight against COVID-19 requires broad access to data, scrupulous checks for bias, and strategies to balance speed and accuracy, according to researchers with AI-based diagnostics and literature-mining...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

Flagship’s Repertoire aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with a cytokine-loaded T cell candidate for cancer. Repertoire Immune Medicines Inc. emerged in...
BioCentury | May 16, 2020
Product Development

A guide to COVID-19 preclinical vaccine modalities

As the number of vaccines in development for COVID-19 climbs past 110, more modalities are starting to be represented in the clinic. As of last week, the COVID-19 vaccine modalities in the clinic were inactivated...
BioCentury | May 12, 2020
Product Development

Vaccine prospects for COVID-19: learnings from a 40-year biotech journey that’s still in progress

I have been in biotech research one way or another for over 40 years. This strange time of quarantine and self-isolation during the COVID-19 outbreak has given me time to reflect on how lessons from...
BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

Genfit’s PPAR agonist fails to resolve NASH Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) fell $10.88 (49%) to $11.22 in after-hours trading Monday after reporting that dual PPARα/δ agonist elafibranor missed the primary endpoint of the Phase III...
BioCentury | May 9, 2020
Product Development

A guide to COVID-19 vaccine modalities in the clinic

Of the more than 90 vaccines in development for COVID-19, at least nine -- spanning nucleic acid, viral vector-based and inactivated vaccines -- are in clinical testing. During infection with SARS-CoV-2, the host proteins ACE2...
Items per page:
1 - 10 of 675